Zacks: Quotient Ltd (QTNT) Receives Average Rating of “Strong Buy” from Analysts
Shares of Quotient Ltd (NASDAQ:QTNT) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $12.50 for the company and are predicting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Quotient an industry rank of 69 out of 257 based on the ratings given to related companies.
QTNT has been the topic of several analyst reports. ValuEngine upgraded Quotient from a “hold” rating to a “buy” rating in a report on Friday, November 16th. Zacks Investment Research upgraded Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, BidaskClub upgraded Quotient from a “sell” rating to a “hold” rating in a report on Tuesday, October 2nd.
QTNT stock traded down $0.33 during midday trading on Friday, hitting $6.64. 1,721,907 shares of the company traded hands, compared to its average volume of 412,233. Quotient has a twelve month low of $2.78 and a twelve month high of $9.02. The company has a market cap of $375.43 million, a PE ratio of -3.29 and a beta of 0.50.
Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $6.25 million during the quarter, compared to the consensus estimate of $5.80 million. On average, sell-side analysts expect that Quotient will post -1.92 earnings per share for the current fiscal year.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.